Anavex Life Sciences Corp (AVXL)

[Jonjones325]

There is such a low bar for Rett. I think any improvement will be seen as a positive and would pave the way for approval. Besides, I believe the trial is being run as a phase 2. Many times, especially with orphan indications, the FDA will convert it to a pivotal if the results are positive. Missling also stated this in the conference call.

With our safety profile, the quality of life benefits seen so far and the preclinical epilepsy data, I believe we have a pretty decent shot. However, I agree that it will definitely look bad if we fail with Rett.